This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.

Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.

Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway Therapies

Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.

Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty Care

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.

Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.

Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RDF865. CME credit will be available until October 3, 2025.

Optimizing Obesity Management Before and After Bariatric Surgery: The Role of Antiobesity Pharmacotherapy to Reduce Weight and Obesity-Related Comorbidities

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 23, 2025.

The Itch We Could Never Scratch: Incorporating New and Emerging Therapies to Alleviate the Burden of Prurigo Nodularis With a Team-Based Approach

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XWR865. CME credit will be available until June 4, 2025.

Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease Management

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RFB865. CME/MOC/AAPA credit will be available until April 8, 2025.

Advancing Patient Care in Chronic Spontaneous Urticaria: Reshaping the Future With Targeted Biologic Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.

Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Rishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.

Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein Occlusions

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosures
Robert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.

Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.
Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.
Other Financial or Material Support in the form of royalties from Springer Publishers.

Medical Director
Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting

Go online to PeerView.com/CDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin condition marked by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extremities. Severe itching contributes to scratching, bleeding, thickening of nodules, and scarring. PN can significantly reduce quality of life, affect sleep and mental health, and hamper participation in activities of daily living and social interaction. Until recently, there were no approved treatments for PN, but one agent has been granted a PN indication, and others are in late-stage development. In this activity, based on a recent live symposium, a panel of experts offers personal guidance on the pathophysiology, burden, and new and promising treatment options for PN. The discussion is enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment. Upon completion of this activity, participants should be better able to: Discuss the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN); Explain how a growing understanding of PN pathophysiology has contributed to the development of novel therapeutic strategies; and Develop individualized treatment plans for PN in accordance with current evidence and expert recommendations using current and emerging treatment options as they become available.

Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.

Go online to PeerView.com/RJF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatologic condition characterized by the occurrence of suppurative, painful lesions, typically in the intertriginous areas. Diagnostic delay is common and is correlated with an increase in disease severity and a decrease in quality of life. While existing treatments are often inadequate and do not help all patients, one biologic agent is approved for the management of HS and a number of other emerging agents are currently undergoing phase 2 and 3 trials. In this activity, experts in dermatology will review symptomatology and provide strategies for making a timely and accurate diagnosis of HS and will offer practical guidance on incorporating existing and emerging therapies into the management of HS, with an emphasis on quality-of-life considerations. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and diagnostic challenges to make a timely and accurate diagnosis of hidradenitis suppurativa; Describe the burdens of disease and impact on quality of life for patients with hidradenitis suppurativa; Recognize the limitations of current therapies for hidradenitis suppurativa; and Apply clinical safety and efficacy data on emerging novel treatments for patients with hidradenitis suppurativa

Go online to PeerView.com/TSR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an expert panel examines the latest evidence for currently approved targeted agents in systemic lupus erythematosus (SLE) and lupus nephritis (LN) and offers personal anecdotes and reflections to illustrate how scientific findings can inform everyday clinical practices and guide individualized approaches to care. Additionally, the panel discusses the need for culturally competent care to ameliorate healthcare disparities offering evidence-based tools and tactics to overcome barriers and improve access to care and health information needs for patients in marginalized populations. Upon completion of this activity, participants should be better able to: Employ best practices related to the diagnosis and assessment of SLE and LN; Describe the pathophysiology of SLE and LN, recognizing targets for therapeutic intervention; Outline the mechanism of action, efficacy, and safety of current targeted therapies for SLE and LN; Select appropriate pharmacologic therapy for individual patients with SLE and LN to ensure long-term survival, achieve the lowest possible disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve the management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.